Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 6.9% After Analyst Upgrade
Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Q4 Earnings Call Highlights
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Better-Than-Expected Earnings
Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Ally Bridge Group NY LLC Acquires Shares of 1,898,112 Taysha Gene Therapies, Inc. $TSHA
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of “Moderate Buy” from Analysts
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of “Moderate Buy” by Analysts
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sukumar Nagendran Sells 260,047 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock
Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates
Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
Taysha: TSHA-102 Presses On With IND Part B Protocol And SAP Amendments
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102
Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update